A fragile site at 10q23 (FRA10A) in a phenytoin-exposed fetus: A case report and review of the literature

Prenatal Diagnosis

Volumn 25, Issue 4, 2005, Pages 318-321

  Morel, Chantal F ^a,c   Duncan, Alessandra M V ^a,c   Désilets, Valérie ^b,c  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

FRA10A; Fragile sites; Methylenetetrahydrofolate reductase; Phenytoin; Prenatal diagnosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); PHENYTOIN;

ADULT; AMNION CELL; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CELL CULTURE; CHROMOSOME 10Q; CHROMOSOME FRAGILE SITE; CULTURE MEDIUM; DNA POLYMORPHISM; FEMALE; FETUS; FETUS BLOOD; FETUS CELL; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; MTHFR GENE; POLYMERASE CHAIN REACTION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

ADULT; AMNIOCENTESIS; ANTICONVULSANTS; CELLS, CULTURED; CHROMOSOME DELETION; CHROMOSOME FRAGILE SITES; CHROMOSOME FRAGILITY; CHROMOSOMES, HUMAN, PAIR 10; EPILEPSY; FEMALE; HUMANS; KARYOTYPING; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHENYTOIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREGNANCY; PREGNANCY COMPLICATIONS;

BISON BONASUS;

EID: 18244386205     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1134     Document Type: Article

References (14)

1. Billing RE. 1984. Decreased hepatic methylenetetrahydrofolate reductase activity in mice after chronic phenytoin treatment. Mol Pharmacol 25: 459-466.
2. Castro R, Rivera I, Ravasco P, et al. 2004. 5-10 methylenetetrahydrofolate reductase (MTFHR) 677C→T and 1298A→C mutations are associated with DNA hypomethylation. J Med Genet 41: 454-458.
3. Friso S, Choi S-W, Girelli D, et al. 2002. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic methylation through an interaction with folate status. Proc Natl Acacl Sci U S A 99: 5606-5611.
4. Frosst P, Blom HJ, Milos R, et al. 1995. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113.
5. Gardner RJ, Sutherland GR. 2004. Chromosome Abnormalities and Genetic Counseling (3rd edn), Oxford University Press: New York; 236-239.
6. Hodges KB, Larson RS, Butler MG. 1998. Chromosome fragile sites in mentally retarded males; increased incidence with seizures and diphenylhydantoin therapy. Ann Clin Lab Sci 28: 293-299.
7. Hsu LYF, Yu M-T, Richkind KE, et al. 1996. Incidence and significance of chromosome mosaicism involving an autosomal structural abnormality diagnosed prenatally through amniocentesis: a collaborative study. Prenat Diagn 16: 1-28.
8. Maltby EL, Higgins S. 1987. Folate sensitive site at 10q23 and its expression as a deletion. J Med Genet 24: 299.
9. Schwahn B, Rozen R. 2001. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 1: 189-201.
10. Sutherland GR. 2003. Rare fragile sites. Cytogenet Genome Res 100: 77-84.
11. Sutherland GR, Baker E. 2000. The clinical significance of fragile sites on human chromosomes. Clin Genet 58: 157-161.
12. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. 1998. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64: 169-172.
13. Yoo JH, Hong SB. 1999. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocystinemia in epileptic patients receiving anticonvulsants. Metabolism 48: 1047-1051.
14. Zaslav AL, Fox JE, Jacob J, et al. 2002. Significance of a prenatally diagnosed del(10)(q23). Am J Med Genet 107: 174-176.